Tempus Collaborates with Gilead on Oncology R&D

Partnership leverages real-world data to advance cancer research and treatments.

Apr. 9, 2026 at 2:11pm

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray image of a molecular structure, glowing against a dark background, conceptually representing the complex biological processes involved in cancer research and drug development.Innovative partnerships leverage real-world data to advance cancer research and bring new treatments to patients.Chicago Today

Tempus, a leading provider of real-world data and analytics for the healthcare industry, has announced a strategic collaboration with Gilead Sciences, a global biopharmaceutical company, to advance oncology research and development through the use of real-world evidence (RWE).

Why it matters

This collaboration combines Tempus' expertise in real-world data and analytics with Gilead's deep experience in oncology drug development, with the goal of accelerating the discovery and development of new cancer treatments. The use of RWE can provide valuable insights that complement traditional clinical trial data, leading to more informed decision-making and potentially faster drug approvals.

The details

Under the terms of the agreement, Tempus will provide Gilead with access to its large, diverse database of real-world clinical, molecular, and outcomes data, which will be used to inform Gilead's oncology research and development efforts. The collaboration will focus on identifying new biomarkers, patient subgroups, and treatment patterns that can inform clinical trial design and support regulatory submissions.

  • The collaboration was announced on April 9, 2026.

The players

Tempus

A leading provider of real-world data and analytics for the healthcare industry.

Gilead Sciences

A global biopharmaceutical company with a focus on oncology drug development.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited to collaborate with Gilead to leverage our real-world data and analytics capabilities to advance oncology research and development.”

— Eric Lefkofsky, Founder and CEO of Tempus

“This collaboration with Tempus will provide us with valuable real-world insights to inform our oncology pipeline and help us bring new treatments to patients faster.”

— Daniel O'Day, Chairman and CEO of Gilead Sciences

What’s next

The collaboration is expected to last for multiple years, with the potential to expand into additional therapeutic areas beyond oncology.

The takeaway

This partnership between Tempus and Gilead demonstrates the growing importance of real-world data and analytics in the drug development process, as companies seek to leverage diverse data sources to accelerate the discovery and approval of new cancer treatments.